

Alberto Espay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4018451/publications.pdf>

Version: 2024-02-01

378
papers

14,831
citations

18887

64
h-index

34195

103
g-index

393
all docs

393
docs citations

393
times ranked

14076
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional neurological disorder and somatic symptom disorder in Parkinson's disease. Journal of the Neurological Sciences, 2022, 433, 120017.	0.3	10
2	Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations. Movement Disorders Clinical Practice, 2022, 9, 183-190.	0.8	15
3	Movement disorders research in 2021: cracking the paradigm. Lancet Neurology, The, 2022, 21, 10-11.	4.9	14
4	Movement disorders associated with neuronal antibodies: a data-driven approach. Journal of Neurology, 2022, 269, 3511-3521.	1.8	10
5	What the VaP? The meaning of "vascular parkinsonism". Parkinsonism and Related Disorders, 2022, 94, 132-134.	1.1	5
6	Uncovering Essential Tremor Genetics: The Promise of Long-Read Sequencing. Frontiers in Neurology, 2022, 13, 821189.	1.1	11
7	Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. Biology, 2022, 11, 535.	1.3	14
8	Conditions associated with ON "state freezing of gait. Movement Disorders Clinical Practice, 2022, 9, 558-559.	0.8	0
9	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Movement Disorders, 2022, 37, 1265-1271.	2.2	9
10	Functional tremor. Journal of the Neurological Sciences, 2022, 435, 120208.	0.3	8
11	Recommendations for Virtual Administration of the PSP Rating Scale. Movement Disorders, 2022, 37, 1960-1961.	2.2	1
12	When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. Journal of Neurology, 2021, 268, 3203-3211.	1.8	16
13	Impaired Saccade Adaptation in Tremor-Dominant Cervical Dystonia "Evidence for Maladaptive Cerebellum. Cerebellum, 2021, 20, 678-686.	1.4	11
14	Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of Neurology, 2021, 89, 91-98.	2.8	23
15	Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension. Journal of Neurology, 2021, 268, 1006-1015.	1.8	5
16	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. Journal of Parkinson's Disease, 2021, 11, 177-186.	1.5	33
17	Teaching Video NeuroImages: Cluster Breathing in Brainstem-Sparing Bihemispheric Cerebral and Cerebellar Lesions. Neurology, 2021, 96, e2243-e2244.	1.5	0
18	Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies. Parkinsonism and Related Disorders, 2021, 82, 7-9.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. <i>Movement Disorders</i> , 2021, 36, 76-82.	2.2	31
20	Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome. <i>Cerebellum</i> , 2021, 20, 300-305.	1.4	8
21	Toward "eScales": Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	0.8	5
22	Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 308-320.	1.7	18
23	Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders. <i>JAMA Neurology</i> , 2021, 78, 88.	4.5	90
24	Progressive Ataxia with Hemiplegic Migraines: a Phenotype of CACNA1A Missense Mutations, Not CAG Repeat Expansions. <i>Cerebellum</i> , 2021, 20, 134-139.	1.4	3
25	Remote delivery of cognitive behavioral therapy to patients with functional neurological disorders: Promise and challenges. <i>Epilepsy and Behavior Reports</i> , 2021, 16, 100469.	0.5	9
26	Quality of life in isolated dystonia: non-motor manifestations matter. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 622-628.	0.9	27
27	Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire. <i>Movement Disorders</i> , 2021, 36, 1392-1400.	2.2	16
28	Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes". <i>Movement Disorders</i> , 2021, 36, 786-787.	2.2	2
29	"Blocker" Induced Tremor. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 449-452.	0.8	4
30	The Logic and Pitfalls of Parkinson's Disease as "Brain- Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	2.2	28
31	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021, 7, 16.	2.5	10
32	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	1.5	56
33	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 100, 119.e7-119.e13.	1.5	19
34	Reply to: "Caps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus". <i>Movement Disorders</i> , 2021, 36, 1043-1044.	2.2	2
35	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021, 28, 1901-1909.	1.7	21
36	Comment on: "Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information". <i>Parkinsonism and Related Disorders</i> , 2021, 86, 133.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 41-47.	1.1	26
38	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.5	14
39	A Multi-center Genome-wide Association Study of Cervical Dystonia. <i>Movement Disorders</i> , 2021, 36, 2795-2801.	2.2	5
40	Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2021, 11, S117-S122.	1.5	9
41	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	1.8	7
42	High cerebrospinal amyloid- β 42 is associated with normal cognition in individuals with brain amyloidosis. <i>EClinicalMedicine</i> , 2021, 38, 100988.	3.2	69
43	Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2840-2852.	2.2	8
44	Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1034-1037.	0.8	2
45	Commentary: Atypical, Early-Onset Dystonia-Parkinsonism with Oculogyric Crises and Anterior Horn Cell Disorder due to a Novel Δ 1 Mutation. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S19-S20.	0.8	1
46	Soluble Amyloid- β Consumption in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1403-1415.	1.2	31
47	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021, 28, 3999-4009.	1.7	2
48	Donanemab in Early Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2021, 385, 666-667.	13.9	14
49	Timing matters: Otological symptoms and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 23-26.	1.1	2
50	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	3.8	80
51	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692.	2.2	20
52	Of Synuclein and Other Demons. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1391-1393.	1.2	4
53	Biphasic (Subtherapeutic) Levodopa-Induced Respiratory Dysfunction in Parkinson Disease. <i>Neurology: Clinical Practice</i> , 2021, 11, e402-e406.	0.8	3
54	Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda. <i>NeuroImage: Clinical</i> , 2021, 30, 102623.	1.4	79

#	ARTICLE	IF	CITATIONS
55	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 159-167.	1.4	8
56	Low soluble amyloid- β 42 is associated with smaller brain volume in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 15-21.	1.1	8
57	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.5	58
58	Hand mechanogram™ in epilepsy partialis continua. <i>Practical Neurology</i> , 2021, 21, 543-545.	0.5	0
59	Internal Versus External Frame of Reference in Functional Movement Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 67-72.	0.9	5
60	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	4.9	94
61	Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. <i>Digital Biomarkers</i> , 2020, 3, 116-132.	2.2	30
62	Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 96-102.	1.1	6
63	The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 295.	4.5	12
64	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	4.9	80
65	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 33-42.	0.9	65
66	The odyssey of complex neurogenetic disorders: From undetermined to positive. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2020, 184, 876-884.	0.7	11
67	The Pseudodystonia of Paroxysmal Sympathetic Hyperactivity: A Reversible PostAnoxic Complication. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 987-989.	0.8	1
68	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	1.5	4
69	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.	4.9	2
70	The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?. <i>Journal of Parkinson's Disease</i> , 2020, 10, S65-S73.	1.5	33
71	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , 2020, 17, 1736-1746.	2.1	20
72	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 553635.	1.7	22

#	ARTICLE	IF	CITATIONS
73	Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus. Movement Disorders, 2020, 35, 1945-1954.	2.2	27
74	Longitudinal Measurements of Glucocerebrosidase activity in Parkinsonâ€™s patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830.	1.7	23
75	Clinical and Demographic Characteristics of Upper Limb Dystonia. Movement Disorders, 2020, 35, 2086-2090.	2.2	9
76	Cognitive Impairment and Blood Pressure Fluctuations. , 2020, , 122-125.		0
77	Corticobasal: The Syndrome versus the Pathology. , 2020, , 126-128.		0
78	Another Case of Vascular Cognitive Impairment?.. , 2020, , 129-132.		0
79	Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study. Frontiers in Neurology, 2020, 11, 406.	1.1	9
80	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. Journal of Neurology, 2020, 267, 2949-2960.	1.8	26
81	Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology. Frontiers in Neuroscience, 2020, 14, 256.	1.4	21
82	Development and Validation of the Orthostatic Tremor Severity and Disability Scale (<sc>OT</sc>â€10). Movement Disorders, 2020, 35, 1796-1801.	2.2	7
83	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. European Journal of Neurology, 2020, 27, 975-984.	1.7	41
84	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurology, The, 2020, 19, 452-461.	4.9	104
85	Outcome measurement in functional neurological disorder: a systematic review and recommendations. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 638-649.	0.9	77
86	Neural activity in functional movement disorders after inpatient rehabilitation. Psychiatry Research - Neuroimaging, 2020, 303, 111125.	0.9	16
87	<i>GBA</i> variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.5	45
88	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
89	The Shaky Six and the â€œSecond Realityâ€, 2020, , 1-10.		0
90	Pieces of a Puzzle?.. , 2020, , 11-24.		0

#	ARTICLE	IF	CITATIONS
91	Disease "Redefinition" A Tough Pill to Swallow. , 2020, , 25-32.		0
92	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
93	Protein Paradox. , 2020, , 41-56.		0
94	The Fault in Our Models. , 2020, , 57-70.		0
95	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
96	Lessons from Oncology. , 2020, , 81-86.		0
97	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
98	Our Living Dissonance. , 2020, , 105-110.		0
99	The Scientific and Lay Narratives. , 2020, , 111-124.		0
100	Challenges Viewed from Afar. , 2020, , 125-132.		0
101	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0
102	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
103	Note Added at Press Time " Reviving LOF. , 2020, , 150-150.		0
104	Teaching NeuroImages: The dentate sign in subacute cerebellar ataxia. Neurology, 2020, 94, e878-e879.	1.5	2
105	Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 426-433.	0.9	49
106	Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.	1.5	103
107	Long-term unsupervised mobility assessment in movement disorders. Lancet Neurology, The, 2020, 19, 462-470.	4.9	181
108	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2020, 94, 144-145.	1.5	2

#	ARTICLE	IF	CITATIONS
109	Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults. JAMA Neurology, 2020, 77, 461.	4.5	43
110	How have advances in genetic technology modified movement disorder nosology?. European Journal of Neurology, 2020, 27, 1461-1470.	1.7	9
111	Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson's disease. Neurobiology of Aging, 2020, 93, 143.e1-143.e4.	1.5	13
112	Thalamic Deep Brain Stimulation for tremor: The critical role of intraoperative testing. Parkinsonism and Related Disorders, 2020, 73, 45-49.	1.1	5
113	Primrose syndrome: Characterization of the phenotype in 42 patients. Clinical Genetics, 2020, 97, 890-901.	1.0	18
114	Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 314-320.	0.9	50
115	Improving anxiety in Parkinson's disease: A cautionary tale about mobile health technologies. Parkinsonism and Related Disorders, 2020, 73, 50-51.	1.1	2
116	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 2020, 7, 449-461.	1.7	44
117	Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia. Tremor and Other Hyperkinetic Movements, 2020, 10, 56.	1.1	2
118	Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects. Journal of Neurology, 2019, 266, 289-297.	1.8	39
119	Telemedicine in Neurological Disorders: Opportunities and Challenges. Telemedicine Journal and E-Health, 2019, 25, 541-550.	1.6	94
120	Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial. Clinical Parkinsonism & Related Disorders, 2019, 1, 41-47.	0.5	29
121	The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C. Cerebellum and Ataxias, 2019, 6, 9.	1.9	9
122	Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction. Movement Disorders, 2019, 34, 1100-1111.	2.2	57
123	Dystonia in atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2019, 66, 25-33.	1.1	25
124	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. Movement Disorders Clinical Practice, 2019, 6, 512-520.	0.8	31
125	Clinical and neural responses to cognitive behavioral therapy for functional tremor. Neurology, 2019, 93, e1787-e1798.	1.5	73
126	Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis. Parkinsonism and Related Disorders, 2019, 62, 122-127.	1.1	26

#	ARTICLE	IF	CITATIONS
127	<p>Orthostatic hypotension and dementia incidence: links and implications</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	1.0	17
128	Feasibility and utility of a clinician dashboard from wearable and mobile application Parkinsonâ€™s disease data. <i>Npj Digital Medicine</i> , 2019, 2, 95.	5.7	33
129	Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.	1.5	89
130	Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease. <i>JAMA Network Open</i> , 2019, 2, e187800.	2.8	54
131	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
132	The â€œbroken wishboneâ€ splenial sign: A diagnostic hallmark for SPG54 spastic ataxia. <i>Journal of the Neurological Sciences</i> , 2019, 403, 114-116.	0.3	1
133	Is There Vascular Parkinsonism?. <i>Current Clinical Neurology</i> , 2019, , 159-162.	0.1	0
134	Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 402, 81-85.	0.3	6
135	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in Î±-synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	0.9	73
136	Functional movement disorders in neurogeriatric inpatients. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2019, 52, 324-329.	0.8	10
137	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	0.9	13
138	The Final Nail in the Coffin of Disease Modification for Dopaminergic Therapies. <i>JAMA Neurology</i> , 2019, 76, 747.	4.5	30
139	Reply to â€œNeuropathological progression of clinical Parkinson disease subtypesâ€. <i>Nature Reviews Neurology</i> , 2019, 15, 361-362.	4.9	0
140	Head tremor at disease onset: an ataxic phenotype of cervical dystonia. <i>Journal of Neurology</i> , 2019, 266, 1844-1851.	1.8	30
141	A roadmap for implementation of patientâ€™centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019, 34, 657-663.	2.2	213
142	The Parkinson's disease eâ€™diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	2.2	43
143	Movement Disorders in Metabolic Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 7.	2.0	9
144	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.5	194

#	ARTICLE	IF	CITATIONS
145	OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 174-178.	1.1	13
146	Clinical Parkinson disease subtyping does not predict pathology. <i>Nature Reviews Neurology</i> , 2019, 15, 189-190.	4.9	42
147	Teaching Video NeuroImages: Slow periodic myoclonus in subacute sclerosing panencephalitis and fulminant Wilson disease. <i>Neurology</i> , 2019, 93, e1410-e1411.	1.5	9
148	Advance care planning in Parkinson's disease: ethical challenges and future directions. <i>Npj Parkinson's Disease</i> , 2019, 5, 24.	2.5	32
149	Should neurologists diagnose and manage functional neurologic disorders? It is complicated. <i>Neurology: Clinical Practice</i> , 2019, 9, 165-167.	0.8	15
150	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	0.9	24
151	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, 31-61.	1.5	45
152	Movement disorders phenomenology in focal motor seizures. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 161-165.	1.1	7
153	Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. <i>Neurology</i> , 2019, 93, e1328-e1338.	1.5	33
154	Movement Disorders in Prionopathies: A Systematic Review. <i>Tremor and Other Hyperkinetic Movements</i> , 2019, 9, .	1.1	0
155	Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis. <i>Neurology</i> , 2018, 90, 746-747.	1.5	12
156	Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 110-112.	1.1	29
157	Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 928-936.	2.2	64
158	Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation. <i>Journal of the Neurological Sciences</i> , 2018, 390, 33-35.	0.3	2
159	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	2.2	275
160	Clinical Reasoning: Importance of clinical phenomenology in the era of genetic testing. <i>Neurology</i> , 2018, 90, e534-e537.	1.5	1
161	Tablet-Based Application for Objective Measurement of Motor Fluctuations in Parkinson Disease. <i>Digital Biomarkers</i> , 2018, 1, 126-135.	2.2	21
162	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 183-190.	0.8	15

#	ARTICLE	IF	CITATIONS
163	Future of Neurologic Examination in Clinical Practice. <i>JAMA Neurology</i> , 2018, 75, 383.	4.5	9
164	Autonomic dysfunction in Parkinson's disease: A prospective cohort study. <i>Movement Disorders</i> , 2018, 33, 391-397.	2.2	108
165	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.	2.2	37
166	Holmes Tremor-Like Phenotype in DYT1 Dystonia. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 206-208.	0.8	3
167	Cognitive fluctuations in Parkinson's disease dementia: blood pressure lability as an underlying mechanism. <i>Journal of Clinical Movement Disorders</i> , 2018, 5, 1.	2.2	8
168	Globular Glial Tauopathy May be Mistaken for Corticobasal Syndrome "Pointers for the Clinician. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 439-441.	0.8	8
169	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. <i>Neurosurgery</i> , 2018, 82, 753-756.	0.6	52
170	Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 94-97.	1.1	20
171	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.	0.9	76
172	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S53-S56.	1.1	63
173	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	1.4	67
174	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018, 33, 21-35.	2.2	79
175	Orthostatic hypotension in Parkinson disease: Impact on health care utilization. <i>Parkinsonism and Related Disorders</i> , 2018, 47, 45-49.	1.1	30
176	Perioral and tongue fasciculations in Kennedy's disease. <i>Neurological Sciences</i> , 2018, 39, 777-779.	0.9	3
177	Dysfunction in emotion processing underlies functional (psychogenic) dystonia. <i>Movement Disorders</i> , 2018, 33, 136-145.	2.2	51
178	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	1.5	48
179	Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 825-845.	1.4	31
180	Q&A with Alberto Espay. <i>Movement Disorders</i> , 2018, 33, 1561-1563.	2.2	0

#	ARTICLE	IF	CITATIONS
181	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	2.2	36
182	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	2.8	225
183	Teaching Video NeuroImages: The signs of dystonic tremor. <i>Neurology</i> , 2018, 91, e1204-e1205.	1.5	1
184	Epileptic chorea: Another window into neural networks?. <i>Journal of the Neurological Sciences</i> , 2018, 394, 138-140.	0.3	0
185	Post-stroke Movement Disorders: The Clinical, Neuroanatomic, and Demographic Portrait of 284 Published Cases. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2388-2397.	0.7	63
186	Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 82-87.	1.1	38
187	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 53-57.	1.1	38
188	Coxa saltans misdiagnosed as functional gait disorder. <i>Neurology</i> , 2018, 91, 276-277.	1.5	0
189	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33
190	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.	4.5	455
191	Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 141-142.	1.1	16
192	Consensus for the measurement of the camptocormia angle in the standing patient. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 1-5.	1.1	49
193	Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?". <i>Movement Disorders</i> , 2018, 33, 1028-1029.	2.2	2
194	Arm Levitation as Initial Manifestation of Creutzfeldt-Jakob Disease: Case Report and Review of the Literature. <i>Tremor and Other Hyperkinetic Movements</i> , 2018, 8, 572.	1.1	5
195	Post-traumatic Functional Mirror Movements in Klippel-Feil Syndrome. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 447-449.	0.8	0
196	Pure Autonomic Failure Versus Prodromal Dysautonomia in Parkinson's Disease: Insights from the Bedside. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 141-144.	0.8	11
197	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	4.9	141
198	The epileptic and nonepileptic spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies. <i>Movement Disorders</i> , 2017, 32, 310-318.	2.2	63

#	ARTICLE	IF	CITATIONS
199	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.	2.2	74
200	Thalamic deep brain stimulation and gait in orthostatic tremor. <i>Movement Disorders</i> , 2017, 32, 937-938.	2.2	3
201	Subthalamic or red nucleus? A puzzling question arising during intraoperative recording for DBS. <i>Clinical Neurophysiology</i> , 2017, 128, 558-560.	0.7	0
202	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.	2.2	145
203	Gaps and controversies in movement disorders: Introduction to the series. <i>Movement Disorders</i> , 2017, 32, 309-309.	2.2	0
204	Prevalence and burden of dysautonomia in advanced Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 796-797.	2.2	18
205	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 2.	2.2	27
206	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	1.5	37
207	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	4.5	60
208	Psychiatric associations of adult-onset focal dystonia phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 595-602.	0.9	76
209	Diagnosis and Treatment of Functional (Psychogenic) Parkinsonism. <i>Seminars in Neurology</i> , 2017, 37, 228-232.	0.5	12
210	Peripheral neuropathy as marker of severe Parkinson's disease phenotype. <i>Movement Disorders</i> , 2017, 32, 1256-1258.	2.2	22
211	Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry. <i>Movement Disorders</i> , 2017, 32, 1240-1244.	2.2	30
212	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. <i>Journal of the Neurological Sciences</i> , 2017, 376, 84-90.	0.3	30
213	Optimizing extended-release carbidopa/levodopa in Parkinson disease. <i>Neurology: Clinical Practice</i> , 2017, 7, 86-93.	0.8	20
214	Teaching Video Neuro Images: Spastic ataxia syndrome. <i>Neurology</i> , 2017, 89, e178-e179.	1.5	3
215	Levodopa and Parkinson Disease "Myths Revisited" Reply. <i>JAMA Neurology</i> , 2017, 74, 1270.	4.5	2
216	App-Based Bradykinesia Tasks for Clinic and Home Assessment in Parkinson's Disease: Reliability and Responsiveness. <i>Journal of Parkinson's Disease</i> , 2017, 7, 741-747.	1.5	16

#	ARTICLE	IF	CITATIONS
217	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	2.8	133
218	Teaching Video Neuro <i>Images</i> : The underrecognized diphasic dyskinesia of Parkinson disease. <i>Neurology</i> , 2017, 89, e83-e84.	1.5	9
219	Is there even such a thing as "idiopathic normal pressure hydrocephalus"? <i>Annals of Neurology</i> , 2017, 82, 1032-1032.	2.8	2
220	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 15-25.	1.7	40
221	Parkinson disease in Gaucher disease. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 7.	2.2	9
222	Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. <i>Journal of Neurology</i> , 2017, 264, 40-48.	1.8	54
223	Rapidly progressive primary progressive aphasia and parkinsonism with novel <i>GRN</i> mutation. <i>Movement Disorders</i> , 2017, 32, 476-478.	2.2	6
224	Parkinson Disease: An Evolutionary Perspective. <i>Frontiers in Neurology</i> , 2017, 8, 157.	1.1	39
225	Biometric Digital Health Technology for Measuring Motor Function in Parkinson's Disease: Results from a Feasibility and Patient Satisfaction Study. <i>Frontiers in Neurology</i> , 2017, 8, 273.	1.1	23
226	The Parkinson Care Advocate: Integrating Care Delivery. <i>Frontiers in Neurology</i> , 2017, 8, 364.	1.1	5
227	The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S2-S8.	0.5	2
228	The Phenomenology of Movement Disorders. , 2017, , 29-41.		2
229	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
230	A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 279-287.	1.5	40
231	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.	4.9	100
232	Computer-Guided Deep Brain Stimulation Programming for Parkinson's Disease. <i>Neuromodulation</i> , 2016, 19, 127-132.	0.4	31
233	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. <i>Movement Disorders</i> , 2016, 31, 1049-1054.	2.2	28
234	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	2.2	464

#	ARTICLE	IF	CITATIONS
235	Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter caseâ€“control study. <i>Epilepsy and Behavior</i> , 2016, 61, 180-184.	0.9	29
236	Misleading Imaging and Clinical Features in Pathologyâ€“Proven Corticobasal Degeneration. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 315-317.	0.8	1
237	â€“Under pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	0.9	75
238	Updated long-term safety from ongoing phase 3 trials of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e97.	1.1	0
239	Advanced therapies in Parkinsonâ€™s disease: Long-term retrospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 104-108.	1.1	39
240	Flamenco dancer posture. <i>Neurology</i> , 2016, 86, 1462-1463.	1.5	3
241	OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 109-115.	0.8	21
242	Integrated safety of levodopaâ€“carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.	2.2	91
243	Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 65-71.	1.1	68
244	Response to: Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinsonâ€™s disease. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 143.	1.1	1
245	Functional dystonia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 139, 235-245.	1.0	24
246	Clinical and demographic characteristics related to onset site and spread of cervical dystonia. <i>Movement Disorders</i> , 2016, 31, 1874-1882.	2.2	39
247	Cautionary optimism: caffeine and Parkinsonâ€™s disease risk. <i>Journal of Clinical Movement Disorders</i> , 2016, 3, 7.	2.2	4
248	24-hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 597-598.	2.2	23
249	Neuropathic Tremor in Chronic Inflammatory Demyelinating Polyneuropathy: The Acquired Equivalent of the Roussyâ€“Levy Syndrome. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 173-175.	0.8	5
250	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
251	Dopamine dysregulation syndrome with psychosis in 24-hour intestinal levodopa infusion for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 152-154.	1.1	7
252	Teaching Video Neuro <i>Images</i> : Faciobrachial dystonic seizures. <i>Neurology</i> , 2016, 86, e60-1.	1.5	7

#	ARTICLE	IF	CITATIONS
253	Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome. <i>Neurology</i> , 2016, 86, 1164-1166.	1.5	8
254	Clinical signs in functional (psychogenic) gait disorders: a brief survey. <i>Journal of Clinical Movement Disorders</i> , 2016, 3, 3.	2.2	17
255	Rhythmical Involuntary Movements (Tremor and Tremor-Like Conditions). , 2016, , 207-263.		1
256	Abnormalities of Muscle Tone. , 2016, , 49-95.		1
257	Axial Disorders of Movement. , 2016, , 361-435.		0
258	Lack of Organization or Coordination of Voluntary Muscle Activity. , 2016, , 155-205.		0
259	Runny nose sign. <i>Neurology: Clinical Practice</i> , 2016, 6, e14-e16.	0.8	2
260	Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user's guide. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 23-29.	1.4	12
261	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
262	Patterned or Repetitive Movements and/or Abnormal Posturing. , 2016, , 265-303.		0
263	Effort-Related Behaviors in Charcot's Lectures on Hysteria. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 203-203.	0.8	0
264	The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2015, 10, 50.	4.4	91
265	Multidisciplinary rehabilitation in Parkinson's disease: A milestone with future challenges. <i>Movement Disorders</i> , 2015, 30, 1011-1013.	2.2	13
266	Diagnostic Performance of the "Huffing and Puffing" Sign in Functional (Psychogenic) Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 29-32.	0.8	38
267	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	2.2	88
268	Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. <i>Neurology</i> , 2015, 85, 742-743.	1.5	3
269	Cognitive profile of LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	2.2	64
270	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.5	112

#	ARTICLE	IF	CITATIONS
271	The power in numbers: Gut microbiota in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 296-298.	2.2	25
272	Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2015, 6, 34.	1.1	22
273	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	2.0	108
274	Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 692-697.	1.1	99
275	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	2.2	199
276	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	2.2	244
277	Diagnosing and treating neurogenic orthostatic hypotension in primary care. <i>Postgraduate Medicine</i> , 2015, 127, 702-715.	0.9	13
278	Stiff-arm syndrome. <i>Neurology</i> , 2015, 85, 1088-1089.	1.5	0
279	Parkinsonism's hyperpyrexia syndrome and deep brain stimulation. <i>Journal of Neurology</i> , 2015, 262, 2780-2782.	1.8	16
280	A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. <i>Nature Genetics</i> , 2015, 47, 39-46.	9.4	245
281	Teaching Video Neuro Images: Semiology and localization of ballistic movements. <i>Neurology</i> , 2014, 83, e56-7.	1.5	2
282	Congenital mirror movements. <i>Neurology</i> , 2014, 82, 1999-2002.	1.5	52
283	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 141.	4.5	211
284	Subthalamic nucleus deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	2.2	68
285	Ribosomal s15: A novel therapeutic target for Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 990-990.	2.2	0
286	Cinnamon in a mouse model of PD. <i>Movement Disorders</i> , 2014, 29, 1466-1466.	2.2	5
287	Amaurotic and ophthalmoplegic presentation of Balint syndrome. <i>Neurology</i> , 2014, 82, 1844-1845.	1.5	1
288	Hydrocephalic Parkinsonism: lessons from normal pressure hydrocephalus mimics. <i>Journal of Clinical Movement Disorders</i> , 2014, 1, 2.	2.2	33

#	ARTICLE	IF	CITATIONS
289	<i>APOE</i>, <i>MAPT</i>, and <i>SNCA</i> Genes and Cognitive Performance in Parkinson Disease. JAMA Neurology, 2014, 71, 1405.	4.5	172
290	Clinician versus machine: Reliability and responsiveness of motor endpoints in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 590-595.	1.1	125
291	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, The, 2014, 13, 141-149.	4.9	547
292	Neurologic complications of electrolyte disturbances and acidâ€base balance. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 365-382.	1.0	47
293	Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement. Movement Disorders, 2014, 29, 1710-1719.	2.2	190
294	Mutations in ZBTB20 cause Primrose syndrome. Nature Genetics, 2014, 46, 815-817.	9.4	79
295	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Movement Disorders, 2014, 29, 756-764.	2.2	53
296	Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. Parkinsonism and Related Disorders, 2014, 20, 647-650.	1.1	36
297	Surgical Treatment of Parkinson Disease. Neurologic Clinics, 2013, 31, 799-808.	0.8	33
298	Long-duration Parkinson's disease: Role of lateralization of motor features. Parkinsonism and Related Disorders, 2013, 19, 77-80.	1.1	34
299	Levodopaâ€carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism and Related Disorders, 2013, 19, 339-345.	1.1	95
300	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurology, The, 2013, 12, 346-356.	4.9	182
301	Dilated Virchowâ€™s spaces and parkinsonism. Movement Disorders, 2013, 28, 589-590.	2.2	17
302	Psychogenic Movement Disorders. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1383-1396.	0.4	41
303	Myoclonus. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1264-1286.	0.4	16
304	Nosography of the â€essentialâ€. Neurology, 2013, 81, 772-773.	1.5	9
305	Commentary for â€Chediakâ€™Higashi syndrome presenting as youngâ€™onset levodopaâ€™responsive parkinsonismâ€. Movement Disorders, 2013, 28, 129-130.	2.2	0
306	Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics. Journal of Parkinson's Disease, 2013, 3, 205-214.	1.5	64

#	ARTICLE	IF	CITATIONS
307	Writing Orthotic Device for the Management of Writer's Cramp. <i>Frontiers in Neurology</i> , 2013, 4, 2.	1.1	6
308	A rare cervical dystonia mimic in adults: congenital muscular torticollis (fibromatosis colli). <i>Frontiers in Neurology</i> , 2013, 4, 6.	1.1	5
309	Sensory feedback in Parkinson's disease patients with "on"-predominant freezing of gait. <i>Frontiers in Neurology</i> , 2013, 4, 14.	1.1	5
310	Atypical Motor and Behavioral Presentations of Alzheimer Disease. <i>Neurologist</i> , 2012, 18, 266-272.	0.4	37
311	"On"-state freezing of gait in Parkinson disease. <i>Neurology</i> , 2012, 78, 454-457.	1.5	178
312	The six gaps in the search of neuroprotection for Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 111-113.	1.4	3
313	Psychogenic facial movement disorders: Clinical features and associated conditions. <i>Movement Disorders</i> , 2012, 27, 1544-1551.	2.2	93
314	Commentary for "Opsoclonus myoclonus syndrome associated with GQ1b antibodies". <i>Movement Disorders</i> , 2012, 27, 1616-1617.	2.2	0
315	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. <i>PLoS ONE</i> , 2012, 7, e43099.	1.1	44
316	Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 880-887.	2.2	35
317	Feasibility of home-based automated Parkinson's disease motor assessment. <i>Journal of Neuroscience Methods</i> , 2012, 203, 152-156.	1.3	95
318	Diagnostic agreement in patients with psychogenic movement disorders. <i>Movement Disorders</i> , 2012, 27, 548-552.	2.2	60
319	Mirror movements in movement disorders: a review. <i>Tremor and Other Hyperkinetic Movements</i> , 2012, 2, .	1.1	40
320	AmÃ©rico Negrette and Huntington's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 711-713.	0.3	4
321	Parkinsonism and Frontotemporal Dementia: The Clinical Overlap. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 343-349.	1.1	48
322	Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio. <i>Movement Disorders</i> , 2011, 26, 913-914.	2.2	14
323	Reply: Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for long-term clinical trials. <i>Movement Disorders</i> , 2011, 26, 1371-1371.	2.2	0
324	The modified bradykinesia rating scale for Parkinson's disease: Reliability and comparison with kinematic measures. <i>Movement Disorders</i> , 2011, 26, 1859-1863.	2.2	152

#	ARTICLE	IF	CITATIONS
325	Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2504-2508.	2.2	126
326	Methylphenidate for gait impairment in Parkinson disease: A randomized clinical trial. <i>Neurology</i> , 2011, 77, e140; author reply e140.	1.5	4
327	Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	13.9	77
328	Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 751-753.	0.9	15
329	Methylphenidate for gait impairment in Parkinson disease. <i>Neurology</i> , 2011, 76, 1256-1262.	1.5	86
330	Postencephalitic parkinsonism and basal ganglia necrosis due to Epstein-Barr virus infection. <i>Neurology</i> , 2011, 76, 1529-1530.	1.5	29
331	A novel <i>DCC</i> mutation and genetic heterogeneity in congenital mirror movements. <i>Neurology</i> , 2011, 77, 1580-1580.	1.5	9
332	The psychogenic toe signs. <i>Neurology</i> , 2011, 77, 508-509.	1.5	16
333	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	2.2	3
334	Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: A decision analysis. <i>Movement Disorders</i> , 2010, 25, 1456-1463.	2.2	40
335	Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations. <i>Movement Disorders</i> , 2010, 25, 1520-1523.	2.2	6
336	Juvenile levodopaâ€‘responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment. <i>Movement Disorders</i> , 2010, 25, 1860-1867.	2.2	3
337	MOTOR TICS, STEREOTYPIES, AND SELF-FLAGELLATION IN PRIMROSE SYNDROME. <i>Neurology</i> , 2010, 75, 284-286.	1.5	23
338	At-home training with closed-loop augmented-reality cueing device for improving gait in patients with Parkinson disease. <i>Journal of Rehabilitation Research and Development</i> , 2010, 47, 573.	1.6	118
339	Hemichoreaâ€‘Hemiballism after Diabetic Ketoacidosis. <i>New England Journal of Medicine</i> , 2010, 363, e27.	13.9	24
340	Management of Motor Complications in Parkinson Disease: Current and Emerging Therapies. <i>Neurologic Clinics</i> , 2010, 28, 913-925.	0.8	18
341	Motor excess during movement: Overflow, mirroring, and synkinesis. <i>Clinical Neurophysiology</i> , 2010, 121, 5-6.	0.7	8
342	Antiâ€‘N-methyl-D-aspartate Receptor Encephalitis. <i>Archives of Neurology</i> , 2010, 67, 250-1.	4.9	24

#	ARTICLE	IF	CITATIONS
343	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2009, 24, 1001-1008.	2.2	104
344	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374.	2.2	138
345	Toxic Movement Disorders: The Approach to the Patient with a Movement Disorder of Toxic Origin. , 2009, , 115-130.		1
346	Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: Preliminary observations. <i>Movement Disorders</i> , 2008, 23, 2357-2362.	2.2	78
347	Chronic isolated hemifacial spasm as a manifestation of epilepsy partialis continua. <i>Epilepsy and Behavior</i> , 2008, 12, 332-336.	0.9	28
348	REVERSIBLE PARKINSONISM AND ATAXIA ASSOCIATED WITH HIGH-DOSE OCTREOTIDE. <i>Neurology</i> , 2008, 70, 2345-2346.	1.5	7
349	Teaching Neuro <i>Image</i> : Oculomasticatory myorhythmia. <i>Neurology</i> , 2008, 70, e25.	1.5	25
350	Lower-body parkinsonism: reconsidering the threshold for external lumbar drainage. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 50-55.	2.7	35
351	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. <i>Neurology</i> , 2007, 69, 1062-1063.	1.5	7
352	Parkinsonism associated with striatal perivascular space dilation. <i>Neurology</i> , 2007, 68, 1540-1540.	1.5	18
353	Isolated diaphragmatic tremor. <i>Neurology</i> , 2007, 69, 689-692.	1.5	25
354	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. <i>Movement Disorders</i> , 2007, 22, 328-333.	2.2	37
355	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. <i>Movement Disorders</i> , 2007, 22, 813-821.	2.2	97
356	Surgical Treatment of Movement Disorders. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 813-825.	1.0	14
357	Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus. <i>Journal of the Neurological Sciences</i> , 2006, 246, 149-152.	0.3	20
358	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.	2.2	11
359	Rigidity and spasms from autoimmune encephalomyelopathies: Stiff-person syndrome. <i>Muscle and Nerve</i> , 2006, 34, 677-690.	1.0	113
360	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	2.8	195

#	ARTICLE	IF	CITATIONS
361	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study. <i>Neurology</i> , 2006, 66, 1941-1943.	1.5	61
362	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1194-1195.	0.9	21
363	Cerebellar limb tremor and inferior olivary hypertrophy. <i>Neurology</i> , 2006, 67, 1250-1250.	1.5	4
364	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	3.7	286
365	A writing device improves writing in primary writing tremor. <i>Neurology</i> , 2005, 64, 1648-1650.	1.5	45
366	Mirror movements in parkinsonism: evaluation of a new clinical sign. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1355-1359.	0.9	96
367	Petrositis in Ramsay Hunt Syndrome With Multiple Cranial Neuropathies. <i>Archives of Neurology</i> , 2005, 62, 1774.	4.9	22
368	Atypical absences and recurrent absence status in an adult with Angelman syndrome due to the UBE3A mutation. <i>Epileptic Disorders</i> , 2005, 7, 227-30.	0.7	12
369	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003, 18, 942-948.	2.2	17
370	Vermian Hypoplasia and Arrested Cerebral Myelination in Two Sisters: Variant of Joubert's Syndrome or a New Syndrome?. <i>Journal of Child Neurology</i> , 2003, 18, 755-762.	0.7	1
371	Episodic coma in a new leukodystrophy. <i>Pediatric Neurology</i> , 2002, 26, 139-142.	1.0	7
372	Recurrence in Pituitary Adenomas in Childhood and Adolescence. <i>Journal of Child Neurology</i> , 2001, 16, 364.	0.7	3
373	Psychogenic movement disorders. , 0, , 164-174.		0
374	Oral and infusion levodopa therapy in the management of Parkinson's disease. , 0, , 63-75.		0
375	Experimental pharmacological agents in the management of Parkinson's disease. , 0, , 83-92.		0
376	Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease. , 0, , 249-264.		0
377	Deep-brain stimulation of the globus pallidus internus in the management of Parkinson's disease. , 0, , 187-194.		0
378	Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson's disease. , 0, , 195-205.		0